Cyclophosphamide for the treatment of Acute Exacerbation of Interstitial Lung Disease: A Review of the Literature Cyclophosphamide and Interstitial Lung Disease

Main Article Content

Ayoub Innabi
Diana Gomez-Manjarres
Bashar Alzghoul
Mwelwa Chizinga
Borna Mehrad
Divya Patel

Keywords

Cyclophosphamide, Interstitial Lung Disease, Acute Exacerbation

Abstract

Acute exacerbation of interstitial lung disease is a serious and life-threatening event. However, little is known about treatment options. Cyclophosphamide has been proposed in randomized clinic trials as a treatment option in progressive cases of scleroderma related interstitial lung disease. However, in acute exacerbation of interstitial lung disease, we found only small case series, and retrospective studies, mostly with no comparative groups which described the role of cyclophosphamide. Results of these studies showed mixed outcome, with no robust evidence that cyclophosphamide adds any benefit in treating acute exacerbations of interstitial lung disease. More well-designed studies including randomized clinical trials are needed to better understand the role of cyclophosphamide during exacerbations of ILD. In this review article we summarize the current evidence on the use of cyclophosphamide in interstitial lung disease with a focus on the acute exacerbation events.

Downloads

Download data is not yet available.
Abstract 331 | PDF Downloads 313

References

[1] P. Spagnolo, W. Wuyts, Acute exacerbations of interstitial lung disease: lessons from idiopathic pulmonary fibrosis, Curr Opin Pulm Med 23(5) (2017) 411-417.
[2] I.N. Park, D.S. Kim, T.S. Shim, C.M. Lim, S.D. Lee, Y. Koh, W.S. Kim, W.D. Kim, S.J. Jang, T.V. Colby, Acute exacerbation of interstitial pneumonia other than idiopathic pulmonary fibrosis, Chest 132(1) (2007) 214-20.
[3] J.W. Song, S.B. Hong, C.M. Lim, Y. Koh, D.S. Kim, Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome, Eur Respir J 37(2) (2011) 356-63.
[4] Y. Toyoda, M. Hanibuchi, J. Kishi, H. Kawano, S. Morizumi, S. Sato, M. Kondo, T. Takikura, T. Tezuka, H. Goto, Y. Nishioka, Clinical features and outcome of acute exacerbation of interstitial pneumonia associated with connective tissue disease, J Med Invest 63(3-4) (2016) 294-9.
[5] V. Cottin, B. Crestani, D. Valeyre, B. Wallaert, J. Cadranel, J.C. Dalphin, P. Delaval, D. Israel-Biet, R. Kessler, M. Reynaud-Gaubert, B. Aguilaniu, B. Bouquillon, P. Carré, C. Danel, J.B. Faivre, G. Ferretti, N. Just, S. Kouzan, F. Lebargy, S. Marchand-Adam, B. Philippe, G. Prévot, B. Stach, F. Thivolet-Béjui, J.F. Cordier, F.N.R. Centre, N.o.C.C.f.R.L. Diseases, Diagnosis and management of idiopathic pulmonary fibrosis: French practical guidelines, Eur Respir Rev 23(132) (2014) 193-214.
[6] W.H. Amundson, E. Racila, T. Allen, H.E. Dincer, R. Tomic, M. Bhargava, D.M. Perlman, H.J. Kim, Acute exacerbation of interstitial lung disease after procedures, Respir Med 150 (2019) 30-37.
[7] W.D. Travis, U. Costabel, D.M. Hansell, T.E. King, D.A. Lynch, A.G. Nicholson, C.J. Ryerson, J.H. Ryu, M. Selman, A.U. Wells, J. Behr, D. Bouros, K.K. Brown, T.V. Colby, H.R. Collard, C.R. Cordeiro, V. Cottin, B. Crestani, M. Drent, R.F. Dudden, J. Egan, K. Flaherty, C. Hogaboam, Y. Inoue, T. Johkoh, D.S. Kim, M. Kitaichi, J. Loyd, F.J. Martinez, J. Myers, S. Protzko, G. Raghu, L. Richeldi, N. Sverzellati, J. Swigris, D. Valeyre, A.E.C.o.I.I. Pneumonias, An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias, Am J Respir Crit Care Med 188(6) (2013) 733-48.
[8] H.R. Collard, C.J. Ryerson, T.J. Corte, G. Jenkins, Y. Kondoh, D.J. Lederer, J.S. Lee, T.M. Maher, A.U. Wells, K.M. Antoniou, J. Behr, K.K. Brown, V. Cottin, K.R. Flaherty, J. Fukuoka, D.M. Hansell, T. Johkoh, N. Kaminski, D.S. Kim, M. Kolb, D.A. Lynch, J.L. Myers, G. Raghu, L. Richeldi, H. Taniguchi, F.J. Martinez, Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report, Am J Respir Crit Care Med 194(3) (2016) 265-75.
[9] N. Enomoto, Y. Oyama, Y. Enomoto, H. Yasui, M. Karayama, M. Kono, H. Hozumi, Y. Suzuki, K. Furuhashi, T. Fujisawa, N. Inui, Y. Nakamura, T. Suda, Differences in clinical features of acute exacerbation between connective tissue disease-associated interstitial pneumonia and idiopathic pulmonary fibrosis, Chron Respir Dis 16 (2019) 1479972318809476.
[10] C.J. Ryerson, V. Cottin, K.K. Brown, H.R. Collard, Acute exacerbation of idiopathic pulmonary fibrosis: shifting the paradigm, Eur Respir J 46(2) (2015) 512-20.
[11] T. Suda, Y. Kaida, Y. Nakamura, N. Enomoto, T. Fujisawa, S. Imokawa, H. Hashizume, T. Naito, D. Hashimoto, Y. Takehara, N. Inui, H. Nakamura, T.V. Colby, K. Chida, Acute exacerbation of interstitial pneumonia associated with collagen vascular diseases, Respir Med 103(6) (2009) 846-53.
[12] G. Leuschner, J. Behr, Acute Exacerbation in Interstitial Lung Disease, Front Med (Lausanne) 4 (2017) 176.
[13] S.A. Papiris, E.D. Manali, L. Kolilekas, C. Triantafillidou, I. Tsangaris, K. Kagouridis, Steroids in idiopathic pulmonary fibrosis acute exacerbation: defenders or killers?, Am J Respir Crit Care Med 185(5) (2012) 587-8.
[14] S. Cuerpo, J. Moisés, F. Hernández-González, M. Benegas, J. Ramirez, M. Sánchez, À. Agustí, J. Sellares, Acute exacerbations of idiopathic pulmonary fibrosis: Does clinical stratification or steroid treatment matter?, Chron Respir Dis 16 (2019) 1479973119869334.
[15] J.S. Lee, A. Fischer, Current and emerging treatment options for interstitial lung disease in patients with rheumatic disease, Expert Rev Clin Immunol 12(5) (2016) 509-20.
[16] A.S. Jee, T.J. Corte, Current and Emerging Drug Therapies for Connective Tissue Disease-Interstitial Lung Disease (CTD-ILD), Drugs 79(14) (2019) 1511-1528.
[17] R.K. Hoyles, R.W. Ellis, J. Wellsbury, B. Lees, P. Newlands, N.S. Goh, C. Roberts, S. Desai, A.L. Herrick, N.J. McHugh, N.M. Foley, S.B. Pearson, P. Emery, D.J. Veale, C.P. Denton, A.U. Wells, C.M. Black, R.M. du Bois, A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma, Arthritis Rheum 54(12) (2006) 3962-70.
[18] T.J. Corte, R. Ellis, E.A. Renzoni, D.M. Hansell, A.G. Nicholson, R.M. du Bois, A.U. Wells, Use of intravenous cyclophosphamide in known or suspected, advanced non-specific interstitial pneumonia, Sarcoidosis Vasc Diffuse Lung Dis 26(2) (2009) 132-8.
[19] H. Barnes, A.E. Holland, G.P. Westall, N.S. Goh, I.N. Glaspole, Cyclophosphamide for connective tissue disease-associated interstitial lung disease, Cochrane Database Syst Rev 1 (2018) CD010908.
[20] A. Perelas, A.V. Arrossi, K.B. Highland, Pulmonary Manifestations of Systemic Sclerosis and Mixed Connective Tissue Disease, Clin Chest Med 40(3) (2019) 501-518.
[21] A. Fernández-Codina, K.M. Walker, J.E. Pope, S.A. Group, Treatment Algorithms for Systemic Sclerosis According to Experts, Arthritis Rheumatol 70(11) (2018) 1820-1828.
[22] D.P. Tashkin, M.D. Roth, P.J. Clements, D.E. Furst, D. Khanna, E.C. Kleerup, J. Goldin, E. Arriola, E.R. Volkmann, S. Kafaja, R. Silver, V. Steen, C. Strange, R. Wise, F. Wigley, M. Mayes, D.J. Riley, S. Hussain, S. Assassi, V.M. Hsu, B. Patel, K. Phillips, F. Martinez, J. Golden, M.K. Connolly, J. Varga, J. Dematte, M.E. Hinchcliff, A. Fischer, J. Swigris, R. Meehan, A. Theodore, R. Simms, S. Volkov, D.E. Schraufnagel, M.B. Scholand, T. Frech, J.A. Molitor, K. Highland, C.A. Read, M.J. Fritzler, G.H.J. Kim, C.H. Tseng, R.M. Elashoff, S.L.S.I. Investigators, Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial, Lancet Respir Med 4(9) (2016) 708-719.
[23] D.P. Tashkin, R. Elashoff, P.J. Clements, J. Goldin, M.D. Roth, D.E. Furst, E. Arriola, R. Silver, C. Strange, M. Bolster, J.R. Seibold, D.J. Riley, V.M. Hsu, J. Varga, D.E. Schraufnagel, A. Theodore, R. Simms, R. Wise, F. Wigley, B. White, V. Steen, C. Read, M. Mayes, E. Parsley, K. Mubarak, M.K. Connolly, J. Golden, M. Olman, B. Fessler, N. Rothfield, M. Metersky, S.L.S.R. Group, Cyclophosphamide versus placebo in scleroderma lung disease, N Engl J Med 354(25) (2006) 2655-66.
[24] G. Zhang, T. Xu, H. Zhang, S. Ye, Q. Wang, L. Zhang, Y. Lei, R. Luo, X. Zhang, [Randomized control multi-center clinical study of mycophenolate mofetil and cyclophosphamide in the treatment of connective tissue disease related interstitial lung disease], Zhonghua Yi Xue Za Zhi 95(45) (2015) 3641-5.
[25] B. Wallace, D. Vummidi, D. Khanna, Management of connective tissue diseases associated interstitial lung disease: a review of the published literature, Curr Opin Rheumatol 28(3) (2016) 236-45.
[26] J. Goldin, R. Elashoff, H.J. Kim, X. Yan, D. Lynch, D. Strollo, M.D. Roth, P. Clements, D.E. Furst, D. Khanna, S. Vasunilashorn, G. Li, D.P. Tashkin, Treatment of scleroderma-interstitial lung disease with cyclophosphamide is associated with less progressive fibrosis on serial thoracic high-resolution CT scan than placebo: findings from the scleroderma lung study, Chest 136(5) (2009) 1333-1340.
[27] D.P. Tashkin, R. Elashoff, P.J. Clements, M.D. Roth, D.E. Furst, R.M. Silver, J. Goldin, E. Arriola, C. Strange, M.B. Bolster, J.R. Seibold, D.J. Riley, V.M. Hsu, J. Varga, D. Schraufnagel, A. Theodore, R. Simms, R. Wise, F. Wigley, B. White, V. Steen, C. Read, M. Mayes, E. Parsley, K. Mubarak, M.K. Connolly, J. Golden, M. Olman, B. Fessler, N. Rothfield, M. Metersky, D. Khanna, N. Li, G. Li, S.L.S.R. Group, Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease, Am J Respir Crit Care Med 176(10) (2007) 1026-34.
[28] O. Kowal-Bielecka, J. Fransen, J. Avouac, M. Becker, A. Kulak, Y. Allanore, O. Distler, P. Clements, M. Cutolo, L. Czirjak, N. Damjanov, F. Del Galdo, C.P. Denton, J.H.W. Distler, I. Foeldvari, K. Figelstone, M. Frerix, D.E. Furst, S. Guiducci, N. Hunzelmann, D. Khanna, M. Matucci-Cerinic, A.L. Herrick, F. van den Hoogen, J.M. van Laar, G. Riemekasten, R. Silver, V. Smith, A. Sulli, I. Tarner, A. Tyndall, J. Welling, F. Wigley, G. Valentini, U.A. Walker, F. Zulian, U. Müller-Ladner, E. Coauthors, Update of EULAR recommendations for the treatment of systemic sclerosis, Ann Rheum Dis 76(8) (2017) 1327-1339.
[29] S.C. Mathai, S.K. Danoff, Management of interstitial lung disease associated with connective tissue disease, BMJ 352 (2016) h6819.
[30] P. Saunders, V. Tsipouri, G.J. Keir, D. Ashby, M.D. Flather, H. Parfrey, D. Babalis, E.A. Renzoni, C.P. Denton, A.U. Wells, T.M. Maher, Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial, Trials 18(1) (2017) 275.
[31] G. Raghu, H.R. Collard, J.J. Egan, F.J. Martinez, J. Behr, K.K. Brown, T.V. Colby, J.F. Cordier, K.R. Flaherty, J.A. Lasky, D.A. Lynch, J.H. Ryu, J.J. Swigris, A.U. Wells, J. Ancochea, D. Bouros, C. Carvalho, U. Costabel, M. Ebina, D.M. Hansell, T. Johkoh, D.S. Kim, T.E. King, Y. Kondoh, J. Myers, N.L. Müller, A.G. Nicholson, L. Richeldi, M. Selman, R.F. Dudden, B.S. Griss, S.L. Protzko, H.J. Schünemann, A.E.J.A.C.o.I.P. Fibrosis, An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management, Am J Respir Crit Care Med 183(6) (2011) 788-824.
[32] M.M. Juarez, A.L. Chan, A.G. Norris, B.M. Morrissey, T.E. Albertson, Acute exacerbation of idiopathic pulmonary fibrosis-a review of current and novel pharmacotherapies, J Thorac Dis 7(3) (2015) 499-519.
[33] K. de Groot, L. Harper, D.R. Jayne, L.F. Flores Suarez, G. Gregorini, W.L. Gross, R. Luqmani, C.D. Pusey, N. Rasmussen, R.A. Sinico, V. Tesar, P. Vanhille, K. Westman, C.O. Savage, E.E.V.S. Group), Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial, Ann Intern Med 150(10) (2009) 670-80.
[34] L. Novelli, R. Ruggiero, F. De Giacomi, A. Biffi, P. Faverio, L. Bilucaglia, S. Gamberini, G. Messinesi, A. Pesci, Corticosteroid and cyclophosphamide in acute exacerbation of idiopathic pulmonary fibrosis: a single center experience and literature review, Sarcoidosis Vasc Diffuse Lung Dis 33(4) (2016) 385-391.
[35] T. Okamoto, H. Ichiyasu, K. Ichikado, H. Muranaka, K. Sato, S. Okamoto, K. Iyonaga, M. Suga, H. Kohrogi, [Clinical analysis of the acute exacerbation in patients with idiopathic pulmonary fibrosis], Nihon Kokyuki Gakkai Zasshi 44(5) (2006) 359-67.
[36] V. Ambrosini, A. Cancellieri, M. Chilosi, M. Zompatori, R. Trisolini, L. Saragoni, V. Poletti, Acute exacerbation of idiopathic pulmonary fibrosis: report of a series, Eur Respir J 22(5) (2003) 821-6.
[37] J.G. Parambil, J.L. Myers, J.H. Ryu, Histopathologic features and outcome of patients with acute exacerbation of idiopathic pulmonary fibrosis undergoing surgical lung biopsy, Chest 128(5) (2005) 3310-5.
[38] F.M. Al-Hameed, S. Sharma, Outcome of patients admitted to the intensive care unit for acute exacerbation of idiopathic pulmonary fibrosis, Can Respir J 11(2) (2004) 117-22.
[39] E. Morawiec, I. Tillie-Leblond, V. Pansini, J. Salleron, M. Remy-Jardin, B. Wallaert, Exacerbations of idiopathic pulmonary fibrosis treated with corticosteroids and cyclophosphamide pulses, Eur Respir J 38(6) (2011) 1487-9.
[40] H. Hozumi, H. Hasegawa, K. Miyashita, H. Yasui, Y. Suzuki, M. Kono, M. Karayama, K. Furuhashi, D. Hashimoto, N. Enomoto, T. Fujisawa, N. Inui, Y. Nakamura, K. Yokomura, H. Nakamura, T. Suda, Efficacy of corticosteroid and intravenous cyclophosphamide in acute exacerbation of idiopathic pulmonary fibrosis: A propensity score-matched analysis, Respirology 24(8) (2019) 792-798.
[41] S. Aso, H. Matsui, K. Fushimi, H. Yasunaga, Systemic glucocorticoids plus cyclophosphamide for acute exacerbation of idiopathic pulmonary fibrosis: a retrospective nationwide study, Sarcoidosis Vasc Diffuse Lung Dis 36(2) (2019) 116-123.
[42] J.M. Naccache, M. Montil, J. Cadranel, M. Cachanado, V. Cottin, B. Crestani, D. Valeyre, B. Wallaert, T. Simon, H. Nunes, Study protocol: exploring the efficacy of cyclophosphamide added to corticosteroids for treating acute exacerbation of idiopathic pulmonary fibrosis; a randomized double-blind, placebo-controlled, multi-center phase III trial (EXAFIP), BMC Pulm Med 19(1) (2019) 75.
[43] B. Bradley, H.M. Branley, J.J. Egan, M.S. Greaves, D.M. Hansell, N.K. Harrison, N. Hirani, R. Hubbard, F. Lake, A.B. Millar, W.A. Wallace, A.U. Wells, M.K. Whyte, M.L. Wilsher, B.i.T.S.S.o.C.C. British Thoracic Society Interstitial Lung Disease Guideline Group, T.S.o. Australia, N.Z.T. Society, I.T. Society, Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society, Thorax 63 Suppl 5 (2008) v1-58.
[44] S.M. Koo, S.Y. Kim, S.M. Choi, H.K. Lee, K.I.L.D.S. Group, Korean Guidelines for Diagnosis and Management of Interstitial Lung Diseases: Part 5. Connective Tissue Disease Associated Interstitial Lung Disease, Tuberc Respir Dis (Seoul) 82(4) (2019) 285-297.
[45] F. Tomiyama, R. Watanabe, T. Ishii, Y. Kamogawa, Y. Fujita, Y. Shirota, K. Sugimura, H. Fujii, H. Harigae, High Prevalence of Acute Exacerbation of Interstitial Lung Disease in Japanese Patients with Systemic Sclerosis, Tohoku J Exp Med 239(4) (2016) 297-305.
[46] M. Ota, Y. Iwasaki, H. Harada, O. Sasaki, Y. Nagafuchi, S. Nakachi, S. Sumitomo, H. Shoda, S. Tohma, K. Fujio, K. Yamamoto, Efficacy of intensive immunosuppression in exacerbated rheumatoid arthritis-associated interstitial lung disease, Mod Rheumatol 27(1) (2017) 22-28.
[47] A.B. Schulze, G. Evers, A. Kümmel, F. Rosenow, J. Sackarnd, J.P. Hering, C. Schülke, J.A. Engelbertz, D. Görlich, P.J. Barth, G. Lenz, H. Becker, M. Mohr, L.H. Schmidt, Cyclophosphamide pulse therapy as treatment for severe interstitial lung diseases, Sarcoidosis Vasc Diffuse Lung Dis 36(2) (2019) 157-166.